SG Americas Securities’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-12,000
Closed -$2K – 3138
2025
Q1
$2K Sell
12,000
-30,000
-71% -$2.15M ﹤0.01% 3432
2024
Q4
$10K Sell
42,000
-517,600
-92% -$36.2M ﹤0.01% 3043
2024
Q3
$592K Buy
559,600
+529,600
+1,765% +$38.5M ﹤0.01% 1536
2024
Q2
$122K Buy
+30,000
New +$2.66M ﹤0.01% 2432
2020
Q2
– Sell
-90,000
Closed -$68K – 3733
2020
Q1
$68K Buy
+90,000
New +$6.49M ﹤0.01% 3110

Other funds holding EW

SG Americas Securities's EW Position: Q2 2026 in Review

SG Americas Securities reduced its Edwards Lifesciences (EW) stake by 43% in Q2 2026, selling an estimated $35.3M and leaving 559,479 shares worth $50.6M. The position accounts for 0.03% of the portfolio, ranked #350.

SG Americas Securities first reported a position in EW in Q2 2013 and has held it in 53 quarters since. The position peaked at $78.5M in Q1 2026. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • SG Americas Securities held 559,479 shares of Edwards Lifesciences worth $50.6M as of Q2 2026.
  • SG Americas Securities sold 421,130 Edwards Lifesciences shares in Q2 2026, an estimated $35.3M.
  • Edwards Lifesciences made up 0.03% of SG Americas Securities's portfolio in Q2 2026, its #350 holding.
  • SG Americas Securities first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
  • SG Americas Securities's Edwards Lifesciences position peaked at $78.5M in Q1 2026.
  • 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.